Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19

NCT04646044 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT04646044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04646044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19
Lead sponsor
Nektar Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 13, 2020
Completion date
May 18, 2021
Enrollment
30 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019, covid-19